Stratagene Expands Rights to Molecular Diagnostics Intellectual Property Portfolio
Complete the form below to unlock access to ALL audio articles.
Stratagene Corporation has announced that it has obtained an exclusive option to evaluate and license a family of patents and patent applications controlled by AROS Applied Biotechnology of Denmark.
Under the terms of the agreement, Stratagene will have the right to evaluate and exclusively license the rights to certain gene groups that have been shown to have predictive capabilities for certain cancers.
"We are very excited about this new agreement with AROS, a leader in gene analysis and PCR-based testing," said Joseph A. Sorge, MD, President and CEO of Stratagene.
"In addition to our ongoing relationships with Bayer Healthcare, Focus Diagnostics and the Sidney Kimmel Cancer Center, we regard this new agreement as another significant milestone for our molecular diagnostics growth strategy."
"Our relationship with Bayer Healthcare currently focuses on customization of our leading-edge Mx3005P instrument systems for use on Bayer's molecular diagnostics testing platform."
"Focus Diagnostics is utilizing our technology, expertise and manufacturing capabilities to develop selected molecular diagnostics kits and products based on certain proprietary FullVelocity technologies."
"With the addition of AROS, we believe we have taken another important step in executing the third facet of our molecular diagnostics strategy, which is focused on developing Stratagene-branded test kits and products."
"Exclusive access to this innovative intellectual property will enable us to continue to progress with our molecular diagnostics strategy," continued Dr. Sorge.
"By using sets of genes that have predictive capabilities for bladder cancer, we believe that we will be able to internally develop diagnostic test kits, which should enable the detection of cancer at an earlier stage than is now possible and provide invaluable guidance to doctors as they make therapeutic decisions to treat cancers."
"We believe that this intellectual property, with its important implications for a variety of cancers, uniquely positions us to bring to market technology that will serve unmet needs within molecular diagnostics."
